EGFR and neoplasm: Because of the higher avidity of the bivalent anti-EGFR TMs, they could direct the Nb-adCAR-T cells to tumor cells with low EGFR expression levels, while the monovalent TMs could only direct the Nb-adCAR-T cells to tumor cells with high EGFR expression levels (86).